Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Down 6.4% in October

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 192,700 shares, a decline of 6.4% from the September 30th total of 205,900 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average daily volume of 535,500 shares, the short-interest ratio is currently 0.4 days.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Aptose Biosciences in a research report on Monday. They set a “hold” rating on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Aptose Biosciences has an average rating of “Moderate Buy” and an average target price of $9.00.

Aptose Biosciences Price Performance

NASDAQ:APTO opened at $0.39 on Thursday. The company has a 50 day moving average price of $0.39 and a 200-day moving average price of $0.71. Aptose Biosciences has a 1-year low of $0.33 and a 1-year high of $3.32. The firm has a market cap of $7.06 million, a price-to-earnings ratio of -0.06 and a beta of 1.26.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.